For MZ SR:
State Secretary MUDr. Viliam Čislák, MPH
Director-General Department of Pharmacy and Drug Policy MUDr. Adam Hlôška

For cystic fibrosis club:
President: Mgr. Andrea Pendant
Member: Mgr. Jaroslav Lexa
expert advisor: main expert of MZ SR for paediatric pneumology, and Phtiseology
Doc. Martin Brezina, CSc.

For health insurance undertakings:
ABP: PharmDr. Lyudmila Krč The only one
Trust: Mgr. Renate Hadyn
Union: doc. PharmDr. Tomáš Tesař, PhD., MBA

The meeting was convened following the conclusions of the meeting carried out on June 12, 2012 in the Slovak Republic.

State Secretary MZ SR welcomed and informed that MZ SR found method of reimbursement of Solmucol for patients with cystic fibrosis (further The Commission notes that the Commission's decision to initiate the formal investigation procedure was published in the Official Journal of the European Union.
He stated that health insurance companies within the meaning of § 88 (8) of Law No 363/2011 on the basis of individual requests from CF patients, this medicinal product may be fully to be paid.
Mgr. Pendant: Presented an analysis of anticipated cost of medicine Solmucol used to diagnose CF in the number of registered patients with CF 400 as well as an analysis of the expected costs of recovery medical condition in the absence of Solmusol in the diagnosis with CF (see Annex).
JUDr. Lex: He pointed out the fact that most patients with CF comes from socially weaker families and treatment by means of writing It is not appropriate to apply for or to derogate from the single exemption as treatment with CF is not appropriate. Solmucol is only one of many medicines that a CF patient must take daily and One family goes to 200 euros a year. For patients with CF, this is the basic medicine, so they are looking for a way to be fully paid by health insurance companies.
He reported that for all health insurance companies it was 400 patients with CF 100,000,-€ per year. He also pointed out that in Slovakia there are six clinic in which patients with CF are treated, writing and dealing exceptions is a complex process not only for clinics, but especially for families with patients with CF.
He asked for the possibility of issuing a general block exemption with specific currencies patients with CF.
Doc. MUDr. Brezina: Clarified the professional treatment side of patients with CF, the need for essential medicinal products, in particular Solmucola. 2 –

Insurance representatives: The situation is more of a technical problem. Differences If a medicinal product is authorised for use in the manufacture of a medicinal product for human use, the use of the product should be authorised. It's a group permit.

MUDr. Number: pointed to the need to find a match to at least one drug has been fully compensated for patients with CF.
MUDr. Hlôška: Recalled that since 25.11.2011 the Decree No. 434/2011 establishing the list of medicinal products intended for supportive use, or additional treatment and therefore Acetylcystein is not possible in terms of valid to include the official price list of medicinal products.
He stressed that the aim of the meeting was to find an optimal solution to the situation. Suggested as the only possible solution that health insurance companies in the group Acetylcystein can issue a mass permit, but they have to do a survey of Acetylcystein at what price.
Doc. Tesař: The above proposal is possible, but insurance companies must enter into negotiations with several producers, then do agreement with suppliers, which is a complex process.
JUDr. Lexa: He stated that this method is possible through public channels procurement, discussed in detail the way and form in public procurement with the possibility of using the derogation.
PharmDr. Single: It showed the cost of treating patients with CF, stressing that the 2011 GZP paid off treatment for CF patients for dg R86 about 800,000,-€.
Doc.MUDr.Brezina + JUDr.Lexa: They said that the number surprised them, a thorough check of the condition is required. Patients with CF Many so that their treatment cannot be checked, patients with CF usually have their pharmacy, where they take the medicine and the pharmacists know about it. They're willing provide an accurate list of patients with both CF and established treatment.
MUDr. Depth: He stressed that health insurance companies would have to carry out a thorough analysis of the situation and come up with a proposal for a solution. He asked for health insurance companies to submit a draft solution by the deadline of early November 2012.

Conclusion:

To convene a working meeting at the level of the Section Director General pharmacy and pharmaceutical policy of MZ SR with all interested parties early November 2012

She wrote: Jell-O

It verified: MUDr. Adam Hlôška, CEO of SFLP,v.r.

Approval: MUDr. Viliam Čislák, MPH, State Secretary MZ SR,v.r.